Eli Lilly (NYSE:LLY) plans to put $473 million on the table to fund a collaboration with Cambridge, Mass.-based startup Sigilon Therapeutics, the insulin-maker reported today.
The goal of the newly-established partnership is to develop encapsulated cell therapies to treat Type I diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes appeared first on MassDevice.